Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51
- 17 September 2008
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 26 (48), 6151-6156
- https://doi.org/10.1016/j.vaccine.2008.08.056
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Randomized, Double‐Blind, Placebo‐Controlled Phase 3 Trial of the Safety and Tolerability of IC51, an Inactivated Japanese Encephalitis VaccineThe Journal of Infectious Diseases, 2008
- A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitisVaccine, 2007
- Japanese encephalitis: development of new candidate vaccinesExpert Review of Anti-infective Therapy, 2006
- Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue virusesNature Medicine, 2004
- TBE vaccination and the Austrian experienceVaccine, 2003
- Short‐Term Safety of Live Attenuated Japanese Encephalitis Vaccine (SA14–14–2): Results of a Randomized Trial with 26,239 SubjectsThe Journal of Infectious Diseases, 1997
- Evaluation of the Potency and Safety of Inactivated Japanese Encephalitis Vaccine in US InhabitantsThe Journal of Infectious Diseases, 1990
- Further experience with Japanese encephalitis vaccineThe Lancet, 1990
- Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human useVaccine, 1988
- Safety of a Live-Attenuated Japanese Encephalitis Virus Vaccine (SA14-14-2) for ChildrenThe American Journal of Tropical Medicine and Hygiene, 1988